Mesoblast Ltd
Company Profile
Business description
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
Contact
55 Collins Street
Level 38
MelbourneVIC3000
AUST: +61 396396036
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2027
Employees
108
Stocks News & Analysis
stocks
3 charts on Anthropic’s historic IPO filing
stocks
Weight loss drugs not an existential threat to undervalued ASX share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,971.40 | 2.60 | 0.03% |
| CAC 40 | 7,887.14 | 39.82 | 0.51% |
| DAX 40 | 25,590.77 | 179.93 | 0.71% |
| Dow JONES (US) | 52,377.57 | 15.99 | 0.03% |
| FTSE 100 | 10,686.54 | 80.79 | -0.75% |
| HKSE | 23,061.04 | 19.72 | 0.09% |
| NASDAQ | 26,477.81 | 308.43 | 1.18% |
| Nikkei 225 | 64,115.56 | 847.19 | 1.34% |
| NZX 50 Index | 13,691.33 | 11.06 | 0.08% |
| S&P 500 | 7,722.60 | 45.83 | 0.60% |
| S&P/ASX 200 | 8,847.30 | 2.80 | -0.03% |
| SSE Composite Index | 3,669.26 | 20.96 | 0.57% |